Objective To investigate the influence of cationic liposomemediated endostatin gene on colorectal cancer liver metastasis. Methods Animal model for colorectal carcinoma liver metastasis were established. The plasmid expressing endostatin genelipofectAMINE were injected in vein. Results After cationic liposomemediated endostatin gene were injected in vein, the incidence of liver metastasis and mean numbers of liver tumors were decreased, survival time of animal was significantly longer. Conclusion Intravenous injection of cationic liposomemediated endostatin gene can control the development of colorectal cancer liver metastasis effectively.
We evaluated the surgical results in 32 patients with liver metastasis from colorectal carcinoma. Twenty four patients had 1-3 metastatic hepatic nodules and 20 patients had synchronous hepatic metastasis. Liver resection was carried out simultaneously with radical resection of the primary tumour in 15 patients, 5 patients experienced resection 2 to 4 weeks later. Liver and primary tumour were resected as a whole in 5 patients with infiltrating metastasis from colonic carcinoma.Other operative types included atypical resections, left lateral lobectom and right posterior lobectomy, and right hemihepatactomy, right trilobectomy.Hepatic metastasis were all documented by pathology. The 3year and 5year survival rate were 37.5% and 25.0%, with no operative death. The authors believed that the number of metastasis is the most important factor influencing the surgical result, and liver resection is an effective form of treatment for patients with resectable liver metastasis from colorectal carcinoma, but the type of surgery shall be choosed reasonably.
Objective To analyze the relationship between Glasgow prognostic score （GPS）， liver metastasis， and prognosis of rectal caner. Methods Clinical data of 223 patients with rectal cancer who underwent operation in Chinese PLA General Hospital from Jun. 2005 to Dec. 2011 were retrospectively analyzed， and the relationship between preoperative GPS score， liver metastasis， and prognosis of rectal cancer were analyzed. Results Preoperative GPS score of patients with rectal cancer was related to invasion depth （P＜0.001）， vascular or lymphatic invasion （P＜0.001）， liver metastasis （P＜0.001）， TNM stage （P＜0.001）， levels of carcinoembryonic antigen （P=0.009）， levels of CA19-9（P＜0.001）， and levels of CA724 （P＜0.001）. Multivariate analysis results revealed that differentiation of tumor （poorly：OR=10.688）， vascular or lymphatic invasion （OR=4.918）， lymph node metastasis （OR=3.359）， and preoperative GPS score （score 2：OR=15.907） were related to liver metastasis；age （RR=2.121）， differentiation of tumor （poorly：RR=2.846）， invasion depth （RR=1.754）， TNM stage （stageⅡ：RR=7.447， stageⅢ：RR=9.030， stage Ⅳ：RR=13.325）， and preoperative GPS score （score 2：RR=2.471） were the independently prognostic factors of rectal cancer. The preo- perative GPS score were related with both liver metastasis and prognosis of rectal cancer. Conclusion Preoperative GPS score is associated with liver metastasis of rectal cancer， and it is considered to be a useful predictor of postoperative prognosis in rectal cancer.
Objective To investigate the change of immunologic gene expression in cases of colorectal cancer with liver metastasis. Methods The total RNAs were extracted from tumor tissues of original lesions in 16 patients with colorectal cancer， DNA microarray was used to examine the change of immunologic gene expression in colorectal cancer patients with or without liver metastasis. Results Compared with samples without liver metastases， the expressions of 11 immunologic genes obviously down-regulated in the tumor tissues of colorectal cancer patients with liver metastasis， including：carboxypeptidase D；Fc fragment of IgE， high affinityⅠreceptor for gamma polypeptide；Fc fragment of IgG， low affinityⅢa receptor （CD16a）；free fatty acid receptor 2；interleukin 2 receptor gamma；protein tyrosine phosphatase receptor type C；complement factor B；major histocompatibility complex， classⅡ， DM alpha；major histocompatibility complex， classⅡ， DM beta；major histocompatibility complex， classⅡ， DQ alpha 1；granzyme B. The functions involved the growth and activation of immunologic cell， signal transduction， cell apoptotic， cell factors， receptors， complement， apoptotic， and immunogenicity of tumor cell. Conclusions Down-regulation of a various of immunologic gene expression in colorectal cancer patients with liver metastasis inhibits the function of immunology， and tumor cells escaped the destruction of immunology system results in metastasis.
ObjectiveTo evaluate the clinical application and the efficacy of contrast enhanced ultrasonography (CEUS)guided percutaneous radiofrequency ablation (RFA) in patients with liver metastases. MethodsTotal 136 patients with 219 liver metastatic tumors, which were detected by CEUS before RFA therapy, were analyzed retrospectively. The diamter of tumors was (3.2±1.2) cm. Among them, the largest tumor more than 3 cm in diameter were found in 48.5% (66 patients), and 57.4% (78 patients) were with solitary metastasis. Enhanced CT and (or) MRI, and laboratory tests were applied to evaluate the outcomes after RFA treatment by regular followup. ResultsTumors were not detected by conventional ultrasonography in two cases, and 47.0% (63/134) of the patients with the largest tumor were 0.3 cm larger by CEUS than by conventional ultrasonography. More 40 tumors were detected in 18.4% (25/136) patients by CEUS. Followup ranged from 3 to 68 months (median time of 12 months). Early tumor necrosis rate one month after therapy was 98.2% (215/219 tumors). The incidence of local recurrence, new intrahepatic metastasis, and extrahepatic metastasis was 16.9% (23/136), 38.2% (52/136), and 8.8% (12/136), respectively. Local recurrence and new intrahepatic metastasis happened 2-25 months (median time of 6 months) after treatment. Local recurrence rates of the largest tumors ≥ 3 cm and tumor lt; 3 cm was 22.7% and 11.4%， respectively (P=0.079). The rate of new intrahepatic metastasis for the solitary metastasis cases was significantly lower than that for multiple metastases cases (25.6% versus 55.2%, P=0.000). The 1, 2, 3year survival rates were 82.5%, 64.3%, and 50.1%, and the 1, 2, 3year local recurrence free survival rates were 67.7%, 53.8%, and 38.3%, respetively. Patients with solitary metastasis survived longer than that with multiple metastases (P=0.034). ConclusionPatients with liver metastases treated by CEUSguided percutaneous RFA can get better survival rate, and CEUS is of much value for clinic application.
ObjectiveTo summarize the current status and the management of colorectal cancer liver metastases (CRCLM) in the elderly and to explore the therapeutic principles and methods. MethodsForeign and domestic literatrues on management of CRCLM were reviewed and analyzed. ResultsColorectal cancer was still one of the most common malignancy and the most common site for metastasis was liver. In the past years, the incidence of colorectal cancer in the elderly was gradually going up. A similar outcome can be achieved for the appropriate elder metastasis patients compared to the young group, although they were in worse physical conditions. Surgical resection was still the only possible treatment for cure to the resectable CRCLM, chemotherapy and biological therapy were also valuable adjunct therapies. For unresectable liver metastases, alternative treatments were recommended, such as radiofrequency ablation and hepatic artery infusion, etc. ConclusionAccording to the characteristic of CRCLM and the physical features of the eldrly patients, a better outcome should be obtained through multipledisciplinary individualized therapy.
Objective To evaluate the role of apparent diffusion coefficients (ADC) in assesment of response to chemotherapy in patients with gastrointestinal liver metastasis. MethodsTen patients with liver metastasis （8 from colorectal cancer， 1 from gastric cancer， 1 from esophageal cancer） at Peking University People’s Hospital from April 2006 to April 2007 were included. All of them received chemotherapy （FOLFOX6： 4 cases， XELOX： 3 cases, and FOLFIRI： 1 case in 8 cases of colorectal liver metastases; ECF: 1 case of gastric liver metastases; DCF: 1 case of esophageal liver metastasis）. ADC were calculated after MR duffusionweight imaging exmination (GE MEDICAL SYSTEMS HD EXCITE 1.5 T) 1 month pre-and post-chemotherapy, respectively. Tumour response to chemotherapy was assessed by RECIST criteria. ResultsTumors with low pretreatment ADC (lt;9.04×10－4 mm2/s) responded better to chemotherapy than that with high ADC (gt;9.04×10－4 mm2/s); pretreatment ADC of cases (6/10) were remarkable lower than those of cases (4/10)， P＝0.033. Increased ADC after onemonth chemotherapy in patients with liver metastasis predicted a better response. ConclusionsLow pretreatment ADC is predictive of better response to chemotherapy. An increased ADC after treatment predicts a better response to chemotherapy.
ObjectiveTo understand the latest progress of conversion therapies on increasing surgical resection rate of patients with liver metastasis from colorectal carcinoma, evaluate the clinical value of prognostic evaluation model in surgical resection of patients with liver metastasis from colorectal carcinoma, further offer guidance in comprehensive treatment to control disease and improve the quality of life. MethodsThe literatures about new progress in surgical treatment of liver metastasis from colorectal carcinoma at domestic and abroad were reviewed, including the indication of operation, prognostic evaluation model, and how to increase the resection rate for liver metastasis from colorectal carcinoma patients with conversion therapies. ResultsPart of patients with liver metastasis from colorectal carcinoma could get surgeries after accepting positive conversion therapies.For the patients with liver metastases from colorectal carcinoma did not accepted surgeries all the way, it was a safe and effective treatment method by different conversion therapies such as neoadjuvant chemotherapy, molecular targeted therapy, transcatheter arterial chemoembolization, radiofrequency ablation, and so on, and it could improve the quality of life and prolong the survival time. ConclusionsDoctors should pay attention to conversion therapies of patients with liver metastasis from colorectal carcinoma, and promote the usage of the prognostic evaluation model in liver metastasis from colorectal carcinoma.
ObjectiveTo evaluate the effect of surgical management of neuroendocrine liver metastasis. MethodsLiteratures about the surgical management of neuroendocrine liver metastasis were collected and reviewed. ResultsEffect of surgical treatment for neuroendocrine liver metastasis was confirmed, but the molecular mechanism of tumor formation was more complex, and the recurrence rate of surgery was too high, so a large number of new treatment methods had been developed and used clinically, and had achieved good results. These treatments included external beam radiotherapy, internal radiotherapy, liver transplantation, and targeted therapies. ConclusionComprehensive surgical management will be the direction of surgical management of neuroendocrine liver metastasis.
Objective To establish a prediction model for the 1-, 3-, and 5-year survival rates in patients with gastric cancer liver metastases (GCLM) by analyzing prognostic factors based on the Surveillance, Epidemiology, and End Results (SEER) database. Methods Clinical and pathological data from 591 patients diagnosed with GCLM between 2010 and 2015 were obtained from the SEER database. The population was randomly divided into a training cohort and an internal validation cohort at a 7 to 3 ratio. Independent predictors of GCLM were analyzed using univariate and multifactorial Cox regression. Consequently, nomograms were constructed. The model's accuracy was verified by calibration curve, ROC curve, and the C-index, and the clinical utility of the model was analyzed through decision curve analysis. Results Tumor differentiation grade, surgical status, and chemotherapy were significantly associated with the prognosis of GCLM patients, and these three factors were included in constructing the prognostic model and plotting the nomogram. The C-index was 0.706 (95%CI 0.677 to 0.735) and 0.749 (95%CI 0.710 to 0.788) for the training set and the internal validation cohort, respectively. The results of the ROC curve analysis indicated that the area under the curve (AUC) was over 0.7 at 1, 3, and 5 years for both the training and validation cohorts. Conclusion The prediction model of the GCLM is developed based on the 3 factors, i.e., tumor differentiation grade, surgery, and chemotherapy, and shows good prediction accuracy and thus may promote clinical decision making and individualized treatment of GCLM patients.